Microbot Medical reaffirms 2025 achievements, outlines 2026 milestones including Full Market Release in Q2

Microbot Medical Inc.

Received FDA 510(k) clearance for LIBERTY, first single-use remotely operated robotic system for peripheral endovascular procedures.
Emory University Hospital became first adopter of LIBERTY under Limited Market Release; 100% robotic navigation success in ACCESS PVI trial.
Full Market Release of LIBERTY planned for Q2 2026, coinciding with SIR conference.
Targeting 2.5 million annual peripheral endovascular procedures in U.S.; building pipeline for cardiology and neurovascular spaces.
Expanded IP portfolio to 20 patents granted, 52 applications pending; balance sheet bolstered with non-dilutive grant.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.